Larvol Delta - Calluna-Pharma-Successfully-Completes-Phase-1-Clinical-Study-of-CAL101-a-FirstinClass-Therapeutic-for-Fibrotic-and-FibroInflammatory-Indications

CAL101 - Calluna Pharma

https://www.businesswire.com/news/home/20241023939388/en/Calluna-Pharma-Successfully-Completes-Phase-1-Clinical-Study-of-CAL101-a-First-in-Class-Therapeutic-for-Fibrotic-and-Fibro-Inflammatory-Indications

Oct 23, 2024

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next